---
document_datetime: 2023-09-21 17:44:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/zypadhera-epar-all-authorised-presentations_en.pdf
document_name: zypadhera-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7938507
conversion_datetime: 2025-12-22 00:21:59.044809
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MA (EU) Number Administration Invented    Strength   Pharmaceutical Form Route of            Packaging name Package size Content (concentration)

| EU/1/08/479/001   | Zypadhera   | 210 mg   | Powder and solvent for prolonged release suspension for injection   | Intramuscular use   | powder: vial (glass); solvent: vial (glass), syringe (plastic)   | powder: 210 mg; solvent: 3 ml   | 1 vial + 1 vial + 1 syringe with pre-attached safety needle +3 safety needles   |
|-------------------|-------------|----------|---------------------------------------------------------------------|---------------------|------------------------------------------------------------------|---------------------------------|---------------------------------------------------------------------------------|
| EU/1/08/479/002   | Zypadhera   | 300 mg   | Powder and solvent for prolonged release suspension for injection   | Intramuscular use   | powder: vial (glass); solvent: vial (glass) syringe (plastic)    | powder: 300 mg; solvent: 3 ml   | 1 vial + 1 vial + 1 syringe with pre-attached safety needle + 3 safety needles  |
| EU/1/08/479/003   | Zypadhera   | 405 mg   | Powder and solvent for prolonged release suspension for injection   | Intramuscular use   | powder: vial (glass); solvent: vial (glass) syringe (plastic)    | powder: 405 mg; solvent: 3 ml   | 1 vial + 1 vial + 1 syringe with pre-attached safety needle + 3 safety needles  |